Fig. 3.

a Baseline and repeated values of eGFR during the 6-month therapy for patients with eGFR < 60 ml/min/1.73 m² treated with allopurinol or control therapy. eGFR was not significantly changed at the end of 6 months. b Baseline and repeated values of eGFR during the 6-month therapy for patients treated with allopurinol or control therapy. eGFR was not significantly changed at the end of 6 months (p = 0.2 for allopurinol group vs. baseline value, p = 0.9 for control treatment group vs. baseline value and p = 0.2 compared with two treatment groups at the end of study, respectively). By the end of the first month, compared to baseline values before allopurinol treatment, eGFR was reduced (by 9.3 ± 1.4%, p = 0.2).